Actively Recruiting
Phase 3 Study Comparing SHR-A2102 to Chemotherapy in Women with Recurrent or Metastatic Cervical Cancer After Platinum and PD-L1 Treatment
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-04-06
398
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying SHR-A2102 compared to the investigators choice of chemotherapy for patients with recurrent or metastatic cervical cancer that has not responded to platinum-based chemotherapy and PD-L1 inhibitor treatments. This phase III, open-label, randomized trial aims to evaluate the effectiveness of SHR-A2102 in this patient group, with the goal of improving outcomes for those with advanced cervical cancer. Participants will be assigned to receive either SHR-A2102 for injection or one of several chemotherapy drugs chosen by their investigator, including Pemetrexed Disodium, Gemcitabine Hydrochloride, Topotecan Hydrochloride, or Paclitaxel Albumin bound. The study involves active treatment with these options and monitors the effects over time. During the study, participants will be followed for up to three years to assess overall survival and other outcomes such as progression-free survival, response rates, duration of response, disease control, and safety events. Researchers will also measure blood levels of SHR-A2102 and its metabolites, as well as immune responses to the drug. The study includes regular assessments, safety monitoring, and long-term follow-up to understand the treatment effects and participant health over time.
CONDITIONS
Brief Title
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Research Team
Z
Zhifei Lin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here